U.S. Markets closed

Hemispherx Biopharma, Inc. (HEB)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.34+0.01 (+3.28%)
At close: 3:59PM EDT

0.33 -0.01 (-2.71%)
After hours: 5:50PM EDT

People also watch

Hemispherx Biopharma, Inc.

One Penn Center
1617 JFK Boulevard
Philadelphia, PA 19103
United States

Full Time Employees32

Key Executives

Mr. Thomas K. Equels Esq., M.S., J.D.Exec. Vice Chairman, CEO & Pres778.27kN/A64
Mr. Adam Pascale CPACFO & Chief Accounting Officer222.8kN/A69
Dr. David R. Strayer M.D.Chief Scientific Officer & Medical Director316.81kN/A71
Mr. Wayne S. SpringateSr. VP of OperationsN/AN/A46
Ann Marie E. CoverlyDirector of Admin. & HR and Deputy Investor Relations CoordinatorN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company’s approved products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of sexually transmitted disease infection; and Ampligen, a product approved for sale in Argentina for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; Alferon N Injection for the treatment of various categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other viruses. The company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Hemispherx Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.